Eli Lilly agreed to acquire three vaccine makers—Vaccine Company Inc., Curevo, and LimmaTech Biologics—in deals totaling up to nearly $4 billion. The transactions expand Lilly’s infectious disease portfolio, including a shingles competitor and bacterial vaccine programs supported by platform technologies aimed at durable immune responses. The acquisitions also align with Lilly’s broader shift toward prevention-focused investments, following the company’s hiring and build-out around vaccine leadership. For developers and suppliers, the deal spree may reshape competitive dynamics in vaccine R&D, particularly around adjuvant and antigen-delivery platforms. Key near-term items are the timing of integration, the advancement of clinical programs contributed by the acquired companies, and any updates on regulatory plans tied to existing trials.